Although formal guidelines for pausing or restarting GLP-1 medications during acute illnesses dont exist, clinical judgment often supports temporary discontinuation
Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA
If you experience severe, persistent burning accompanied by significant swelling, redness spreading beyond the injection site, or signs of infection (warmth, pus, fever), contact your GP or healthcare professional promptly
In reality, many people prefer non-medication approaches or a combination of medication and lifestyle support when given effective options and informed choice
Your healthcare provider will want to check your HbA1c levels to make sure the new medication is working for you
Experts dont fully understand what causes NAION, whether youre on GLP-1 drugs or not